G&S Capital’s DexCom DXCM Stock Holding History

G&S Capital’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-200	Closed	-$6K	–	225
2019 Q1	$6K	Buy	+200	New	+$7.03K	﹤0.01%	190

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

G&S Capital's DXCM Position: Q2 2019 in Review

G&S Capital sold out of DexCom (DXCM) in Q2 2019, closing a stake of 200 shares — an estimated $6K sold.

G&S Capital first reported a position in DXCM in Q1 2019 and held it in 1 quarter. The position peaked at $6K in Q1 2019. 418 funds tracked by Wall St. Rank hold DXCM as of Q2 2019.

G&S Capital reported no remaining DexCom position as of Q2 2019 after selling out during the quarter.
G&S Capital sold 200 DexCom shares in Q2 2019, an estimated $6K.
G&S Capital first reported a position in DexCom in Q1 2019 and held it in 1 quarter.
G&S Capital's DexCom position peaked at $6K in Q1 2019.
418 funds tracked by Wall St. Rank held DexCom as of Q2 2019.

Based on G&S Capital's 13F filing for Q2 2019, filed 19 Jul 2019.